By Barbara Obstoj-Cardwell
Last week saw the announcement of two large licensing agreements. First, Gilead Sciences’ subsidiary Kite entered into a deal with BioNTech, whereby the German biotech, mostly in the news due to its COVID-19 vaccine developed with Pfizer, has acquired an R&D platform and clinical manufacturing facility in Maryland. The second deal was US pharma giant Pfizer signing an agreement with Arvinas for rights to the latter’s breast cancer candidate, ARV-471, that could cost it more than $2 billion. On the regulatory front, US biotech bluebird bio gained regulatory approval from the European Commission for its gene therapy Skysona. Also, Albireo received approval from both the US Food and Drug Administration and the European Medicines for its rare liver disease drug Bylvay.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze